References
- Shih DQ, Kwan LY. All roads lead to Rome: update on Rome III criteria and new treatment options. Gastroenterol Rep. 2007;1(2):56–65.
- Dinan TG, Cryan JF. The microbiome-gut-brain axis in health and disease. Gastroenterol Clin North Am. 2017;46(1):77–89.
- Theoharides TC, Tsilioni I, Ren H. Recent advances in our understanding of mast cell activation - or should it be mast cell mediator disorders? Expert Rev Clin Immunol. 2019;18:1–18.
- Zhang L, Song J, Hou X. Mast cells and irritable bowel syndrome: from the bench to the bedside. J Neurogastroenterol Motil. 2016;22(2):181–192.
- Lee KN, Lee OY. The role of mast cells in irritable bowel syndrome. Gastroenterol Res Pract. 2016;2016:2031480.
- Burns G, Carroll G, Mathe A, et al. Evidence of local and systemic immune activation in functional dyspepsia and the irritable bowel syndrome: a systemic review. Am J Gastroenterol. 2019;114(3):429–436.
- Afrin LB, Self S, Menk J, et al. Characterization of mast cell activation syndrome. Am J Med Sci. 2017;353(3):207–215.
- Valent P, Akin C, Bonadonna P, et al. Proposed diagnostic algorithm for patients with suspected mast cell activation syndrome. J Allergy Clin Immunol Pract. 2019;7(4):1125–1133.
- Maintz L, Novak N. Histamine and histamine intolerance. Am J Clin Nutr. 2007;85(5):1185–1196.
- Kovacova-Hanuskova E, Buday T, Gavliakova S, et al. Histamine, histamine intoxication and intolerance. Allergol Immunopathol. 2015;43(5):498–506.
- Wilder-Smith CH, Olesen SS, Materna A, et al. Fermentable sugar ingestion, gas production, and gastrointestinal and central nervous system symptoms in patients with functional disorders. Gastroenterology. 2018;155(4):1034–1044.
- Ridolo E, Incorvaia C, Martignago I, et al. Sex in respiratory and skin allergies. Clin Rev Allerg Immunol. 2019;56(3):322–332.
- Fabisiak A, Włodarczyk J, Fabisiak N, et al. Targeting histamine receptors in irritable bowel syndrome: a critical appraisal. J Neurogastroenterol Motil. 2017;23(3):341–348.
- Boeckxstaens GE, Wouters MM. Neuroimmune factors in functional gastrointestinal disorders: a focus on irritable bowel syndrome. Neurogastroenterol Motil. 2017;29(6):e13007.
- Keshteli AH, Madsen KL, Mandal R, et al. Comparison of the metabolomic profiles of irritable bowel syndrome patients with ulcerative colitis patients and healthy controls: new insights into pathophysiology and potential biomarkers. Aliment Pharmacol Ther. 2019;49(6):723–732.